VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of VITRAKVI® (larotrectinib) capsules brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the VITRAKVI® (larotrectinib) capsules medicine cost price in India.
The order for VITRAKVI® (larotrectinib) capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Larotrectinib is used to treat certain tumors that are caused by an abnormal "NTRK" gene. Larotrectinib is used when the cancer has spread to other parts of the body or cannot be removed with surgery or other cancer treatments.
VITRAKVI® (larotrectinib) capsules, for oral use VITRAKVI® (larotrectinib) oral solution Initial U.S. Approval: 2018
Generic Name: larotrectinib
• Capsules: 25 mg, 100 mg
• Oral Solution: 20 mg/mL
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand VITRAKVI® (larotrectinib) capsules on prescription and Import License in Patient's Name only.
For overseas patients, VITRAKVI® (larotrectinib) capsules can be made available in Send your enquiry to find VITRAKVI® (larotrectinib) capsules in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For VITRAKVI® (larotrectinib) capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval For More Details
Bayer’s Vitrakvi first tumor agnostic drug to get EMA license For More Details